Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

• Main Authors: Cheng A., Thongprasert S., Lim H., Sukeepaisarnjaroen W., Yang T., Wu C., Chao Y., Chan S., Kudo M., Ikeda M., Kang Y., Pan H., Numata K., Han G., Balsara B., Zhang Y., Rodriguez A., Wang Y., Poon R.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84987909452&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42670
• Institution: Chiang Mai University

© 2016 by the American Association for the Study of Liver Diseases Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogen...